Carolina Wealth Advisors LLC lifted its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 505.9% in the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 10,034 shares of the company's stock after purchasing an additional 8,378 shares during the period. Carolina Wealth Advisors LLC's holdings in Novo Nordisk A/S were worth $697,000 at the end of the most recent quarter.
Other large investors have also recently modified their holdings of the company. GQG Partners LLC boosted its position in Novo Nordisk A/S by 74.7% during the 4th quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock valued at $1,117,790,000 after acquiring an additional 5,556,460 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Novo Nordisk A/S during the 4th quarter valued at $404,910,000. Loomis Sayles & Co. L P boosted its position in Novo Nordisk A/S by 34.2% during the 4th quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company's stock valued at $995,397,000 after acquiring an additional 2,947,771 shares in the last quarter. Nuveen Asset Management LLC boosted its position in Novo Nordisk A/S by 73.2% during the 4th quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company's stock valued at $537,189,000 after acquiring an additional 2,639,693 shares in the last quarter. Finally, Two Sigma Investments LP bought a new stake in Novo Nordisk A/S during the 4th quarter valued at $158,657,000. Hedge funds and other institutional investors own 11.54% of the company's stock.
Novo Nordisk A/S Price Performance
Novo Nordisk A/S stock traded up $0.80 during midday trading on Friday, reaching $68.50. The company had a trading volume of 5,624,379 shares, compared to its average volume of 7,239,527. The company has a market capitalization of $305.85 billion, a P/E ratio of 20.27, a P/E/G ratio of 1.22 and a beta of 0.66. Novo Nordisk A/S has a 12-month low of $57.00 and a 12-month high of $145.99. The firm's fifty day simple moving average is $69.11 and its 200-day simple moving average is $77.04. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56.
Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.92. The business had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.
Analyst Upgrades and Downgrades
Several analysts have issued reports on the company. Guggenheim cut Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Wall Street Zen raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Saturday, June 14th. BNP Paribas initiated coverage on Novo Nordisk A/S in a report on Tuesday, April 15th. They set an "underperform" rating for the company. Finally, BMO Capital Markets reissued a "market perform" rating and issued a $64.00 price objective (down previously from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $112.00.
Get Our Latest Research Report on Novo Nordisk A/S
About Novo Nordisk A/S
(
Free Report)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Featured Articles
Before you consider Novo Nordisk A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.
While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
